vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Mistras Group, Inc. (MG). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $181.5M, roughly 1.0× Mistras Group, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 2.1%, a 11.3% gap on every dollar of revenue. On growth, Mistras Group, Inc. posted the faster year-over-year revenue change (5.1% vs -1.8%). Mistras Group, Inc. produced more free cash flow last quarter ($26.0M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -0.8%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
AMPH vs MG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $181.5M |
| Net Profit | $24.4M | $3.8M |
| Gross Margin | 46.8% | 28.4% |
| Operating Margin | 19.4% | 7.0% |
| Net Margin | 13.3% | 2.1% |
| Revenue YoY | -1.8% | 5.1% |
| Net Profit YoY | -35.7% | -27.4% |
| EPS (diluted) | $0.51 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $181.5M | ||
| Q3 25 | $191.8M | $195.5M | ||
| Q2 25 | $174.4M | $185.4M | ||
| Q1 25 | $170.5M | $161.6M | ||
| Q4 24 | $186.5M | $172.7M | ||
| Q3 24 | $191.2M | $182.7M | ||
| Q2 24 | $182.4M | $189.8M | ||
| Q1 24 | $171.8M | $184.4M |
| Q4 25 | $24.4M | $3.8M | ||
| Q3 25 | $17.4M | $13.1M | ||
| Q2 25 | $31.0M | $3.0M | ||
| Q1 25 | $25.3M | $-3.2M | ||
| Q4 24 | $38.0M | $5.2M | ||
| Q3 24 | $40.4M | $6.4M | ||
| Q2 24 | $37.9M | $6.4M | ||
| Q1 24 | $43.2M | $995.0K |
| Q4 25 | 46.8% | 28.4% | ||
| Q3 25 | 51.4% | 29.8% | ||
| Q2 25 | 49.6% | 29.1% | ||
| Q1 25 | 50.0% | 25.3% | ||
| Q4 24 | 46.5% | 26.5% | ||
| Q3 24 | 53.3% | 26.8% | ||
| Q2 24 | 52.2% | 27.1% | ||
| Q1 24 | 52.4% | 25.0% |
| Q4 25 | 19.4% | 7.0% | ||
| Q3 25 | 13.2% | 10.4% | ||
| Q2 25 | 24.2% | 4.5% | ||
| Q1 25 | 21.9% | -0.6% | ||
| Q4 24 | 24.2% | 6.1% | ||
| Q3 24 | 29.8% | 6.5% | ||
| Q2 24 | 30.3% | 6.3% | ||
| Q1 24 | 27.9% | 3.0% |
| Q4 25 | 13.3% | 2.1% | ||
| Q3 25 | 9.0% | 6.7% | ||
| Q2 25 | 17.8% | 1.6% | ||
| Q1 25 | 14.8% | -2.0% | ||
| Q4 24 | 20.4% | 3.0% | ||
| Q3 24 | 21.1% | 3.5% | ||
| Q2 24 | 20.8% | 3.4% | ||
| Q1 24 | 25.1% | 0.5% |
| Q4 25 | $0.51 | $0.12 | ||
| Q3 25 | $0.37 | $0.41 | ||
| Q2 25 | $0.64 | $0.10 | ||
| Q1 25 | $0.51 | $-0.10 | ||
| Q4 24 | $0.74 | $0.17 | ||
| Q3 24 | $0.78 | $0.20 | ||
| Q2 24 | $0.73 | $0.20 | ||
| Q1 24 | $0.81 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $28.0M |
| Total DebtLower is stronger | $608.7M | $178.0M |
| Stockholders' EquityBook value | $788.8M | $235.1M |
| Total Assets | $1.6B | $578.8M |
| Debt / EquityLower = less leverage | 0.77× | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $28.0M | ||
| Q3 25 | $276.2M | $27.8M | ||
| Q2 25 | $231.8M | $20.0M | ||
| Q1 25 | $236.9M | $18.5M | ||
| Q4 24 | $221.6M | $18.3M | ||
| Q3 24 | $250.5M | $20.4M | ||
| Q2 24 | $217.8M | $17.2M | ||
| Q1 24 | $289.6M | $16.9M |
| Q4 25 | $608.7M | $178.0M | ||
| Q3 25 | $608.6M | $202.3M | ||
| Q2 25 | $607.7M | $189.4M | ||
| Q1 25 | $603.9M | $171.9M | ||
| Q4 24 | $601.6M | $169.6M | ||
| Q3 24 | $596.4M | $189.7M | ||
| Q2 24 | $586.9M | $199.7M | ||
| Q1 24 | $594.0M | $198.4M |
| Q4 25 | $788.8M | $235.1M | ||
| Q3 25 | $776.7M | $227.4M | ||
| Q2 25 | $757.5M | $215.8M | ||
| Q1 25 | $751.3M | $198.7M | ||
| Q4 24 | $732.3M | $198.6M | ||
| Q3 24 | $727.7M | $205.2M | ||
| Q2 24 | $713.3M | $193.2M | ||
| Q1 24 | $672.4M | $187.1M |
| Q4 25 | $1.6B | $578.8M | ||
| Q3 25 | $1.7B | $596.3M | ||
| Q2 25 | $1.6B | $571.0M | ||
| Q1 25 | $1.6B | $526.8M | ||
| Q4 24 | $1.6B | $523.0M | ||
| Q3 24 | $1.5B | $551.7M | ||
| Q2 24 | $1.5B | $548.1M | ||
| Q1 24 | $1.6B | $542.1M |
| Q4 25 | 0.77× | 0.76× | ||
| Q3 25 | 0.78× | 0.89× | ||
| Q2 25 | 0.80× | 0.88× | ||
| Q1 25 | 0.80× | 0.87× | ||
| Q4 24 | 0.82× | 0.85× | ||
| Q3 24 | 0.82× | 0.92× | ||
| Q2 24 | 0.82× | 1.03× | ||
| Q1 24 | 0.88× | 1.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $32.1M |
| Free Cash FlowOCF − Capex | $24.6M | $26.0M |
| FCF MarginFCF / Revenue | 13.4% | 14.3% |
| Capex IntensityCapex / Revenue | 4.5% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.35× | 8.55× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $8.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $32.1M | ||
| Q3 25 | $52.6M | $4.5M | ||
| Q2 25 | $35.6M | $-9.3M | ||
| Q1 25 | $35.1M | $5.6M | ||
| Q4 24 | $29.0M | $25.7M | ||
| Q3 24 | $60.0M | $19.4M | ||
| Q2 24 | $69.1M | $4.5M | ||
| Q1 24 | $55.3M | $604.0K |
| Q4 25 | $24.6M | $26.0M | ||
| Q3 25 | $47.2M | $-4.1M | ||
| Q2 25 | $25.0M | $-14.7M | ||
| Q1 25 | $24.4M | $1.1M | ||
| Q4 24 | $16.6M | $22.1M | ||
| Q3 24 | $46.2M | $14.6M | ||
| Q2 24 | $63.1M | $-284.0K | ||
| Q1 24 | $46.5M | $-4.2M |
| Q4 25 | 13.4% | 14.3% | ||
| Q3 25 | 24.6% | -2.1% | ||
| Q2 25 | 14.3% | -7.9% | ||
| Q1 25 | 14.3% | 0.7% | ||
| Q4 24 | 8.9% | 12.8% | ||
| Q3 24 | 24.1% | 8.0% | ||
| Q2 24 | 34.6% | -0.1% | ||
| Q1 24 | 27.1% | -2.3% |
| Q4 25 | 4.5% | 3.4% | ||
| Q3 25 | 2.8% | 4.4% | ||
| Q2 25 | 6.1% | 2.9% | ||
| Q1 25 | 6.3% | 2.8% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 2.6% | ||
| Q2 24 | 3.3% | 2.5% | ||
| Q1 24 | 5.1% | 2.6% |
| Q4 25 | 1.35× | 8.55× | ||
| Q3 25 | 3.03× | 0.34× | ||
| Q2 25 | 1.15× | -3.07× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 4.96× | ||
| Q3 24 | 1.48× | 3.02× | ||
| Q2 24 | 1.82× | 0.71× | ||
| Q1 24 | 1.28× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MG
Segment breakdown not available.
